Influenza Medication Market By Size, Demand Analysis, Regions and Forecast - 2031

The global influenza medication market is anticipated to grow at a considerable CAGR of 7.2% during the forecast period (2024-2031). All the major players in the influenza medication market are involved in strategic alliances like acquisitions, partnerships, collaborations, and the launching of new drugs and vaccines to provide advanced treatment for influenza disease globally. Recently, in January 2022, the ResVax vaccine, a vaccine developed by Novavax Co. for RSV disease has completed its phase four trial and the outcomes have been announced at the IDSOG meeting. Emergent BioSolutions Co. has also developed a vaccine for influenza treatment named NuThrax anthrax Vaccine.

Get Free Sample link @ https://www.omrglobal.com/request-sample/influenza-medication-market

For this, the company has enrolled patients to start their phase three trial for a clinical study. This vaccine will help to improve the immune system of the body to fight influenza. In December 2019, Genentech, Inc. also had announced the FDA approval of Xofluza a type of Baloxavir Marboxil for an individual at an elevated risk of developing influenza-related complications. Similarly, in November 2020, Shionogi & Co. announced the filing of a supplemental new drug application for Xofluza, a kind of Baloxavir marboxil drug in Japan for treating influenza virus infection. Moreover, in February 2018, this company has also announced the approval of Xofluza 20 mg tablets for oral administration for the treatment of influenza type A and type B in patients over 12 in Taiwan.

Full report of Influenza Medication Market available @ https://www.omrglobal.com/industry-reports/influenza-medication-market

Market Coverage

Segment Covered- 

• By Treatment type
• By Route of Administration
• By Distribution Channel

Regions Covered- 

• North America
• Europe
• Asia-Pacific
• Rest of the World

Competitive Landscape - BIOCRYST PHARMACEUTICALs, INC., Genentech, Inc., GlaxoSmithKline Plc., Lupin Ltd., Seqirus (CSL), and others

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How COVID-19 impacted the market?

o             Deviation from the pre-COVID-19 forecast

o             Most affected region and segment

• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Influenza Medication Market Report Segment

By Treatment Type

• Baloxavir Marboxil
• Oseltamivir Phosphate
• Others

By Route of Administration

• Oral 
• Others

By Distribution Channel 

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Reasons to Buying From us -

1. We cover more than 15 major industries, further segmented into more than 90 sectors.
2. More than 120 countries are for analysis.
3. Over 100+ paid data sources mined for investigation.
4. Our expert research analysts answer all your questions before and after purchasing your report.

For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/influenza-medication-market

Media Contact:

Contact Person: Mr. Anurag Tiwari
Email: anurag@omrglobal.com
Contact no: +91 780-304-0404
Company Name: Orion Market Research

About Orion Market Research

Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services. The company also offers Digital Marketing services through its subsidiary OMR Digital and Software development and Consulting Services through another subsidiary Encanto Technologies.

Article source: https://article-realm.com/article/Business/70113-Influenza-Medication-Market-By-Size-Demand-Analysis-Regions-and-Forecast-2031.html